Omnicell (NASDAQ:OMCL) Updates FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.650-1.850 for the period, compared to the consensus earnings per share estimate of 1.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Analyst Ratings Changes

A number of research firms have recently commented on OMCL. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Wells Fargo & Company lowered their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Bank of America dropped their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. JPMorgan Chase & Co. cut their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Finally, Benchmark reiterated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Down 1.0 %

Shares of NASDAQ:OMCL opened at $35.01 on Friday. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.75. The business has a fifty day moving average price of $39.01 and a two-hundred day moving average price of $42.57. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company has a market capitalization of $1.64 billion, a PE ratio of 129.67, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Analysts forecast that Omnicell will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.